The Cancer Tissue Diagnostic Market has exhibited an ascending trend, where its value is estimated to go from USD 15,302.2 million in 2024 to USD 23,516.2 million in 2034. Adoption of cancer tissue diagnostics is exhibiting a CAGR of 4.5% from 2024 to 2034. The market was valued at USD 14,651.0 million in 2023 and is anticipated to exhibit a y-o-y growth of 4.4% in 2024.
| Attributes | Key Insights |
|---|---|
| Base Value (2023) | USD 14,651.0 million |
| Global Cancer Tissue Diagnostic Market Size (2024E) | USD 15,302.2 million |
| Cancer Tissue Diagnostic Market Value (2034F) | USD 23,516.2 million |
| Value-based CAGR (2024 to 2034) | 4.5% |
The market witnessed remarkable expansion in recent years due to the growing demand for high-throughput cancer tissue diagnostic kits. This increase in demand for cancer tissue diagnostics is due to its ability to quickly process a large volume of samples and provide effective diagnostic solutions.
Growing demand for genetic testing and analysis of personalized medicine and genomic research & developments is further anticipating market growth. The market is set to surge as several pharmaceutical companies invest in developing and manufacturing sophisticated cancer tissue diagnostics.
Exclusive Offer: 30% Off on Regional Reports
Get a free sample report and customize your regions for a 30% discount on your regional report!
The global cancer tissue diagnostic market recorded a historical CAGR of 3.4% from 2019 to 2023. Historical factors such as the dependency on hospitals, specialty centers, and diagnostics centers have contributed to the development of innovative technologies in cancer tissue diagnostics. Innovative technologies have significantly enhanced the efficiency of diagnostics processes in pharmacogenomics, genetic disorders, and oncology disease diagnosis, leading to increased applications.
Looking forward to the future, the market is projected to grow significantly. The shift is majorly attributed to the rising preference of healthcare professionals for early diagnosis and prognosis of cancer. Growing emphasis on personalized cancer treatments and the development of targeted therapies is fueling growth of cancer tissue diagnostics kits.
Strategic initiatives such as mergers and acquisitions taken by manufacturing companies to develop new products are projected to further propel market growth. The rapid development of technology and innovative diagnostic methodologies have prompted market players to boost their product offerings and enhance their market presence.
For instance, in March 2021, United States-based Agilent Technologies Inc. acquired Resolution Bioscience to strengthen its leadership position in cancer diagnostics. Hence, these strategic collaborations and acquisitions aim to develop innovative solutions to address emerging market needs and stay at the forefront of innovations in cancer diagnostics.
The rising prevalence of different types of cancers among the general population has majorly contributed to the growing adoption of cancer tissue diagnosis in the healthcare fraternity.
Rising demand for technologically progressed diagnostics for effective diagnosis has encouraged manufacturers to develop diagnostic kits that are efficient and affordable. This thriving landscape of clinical trials in research & development of novel cancer diagnostics is set to contribute to the growth of the market by 2034.
Growing application of cutting-edge molecular diagnostics technologies, such as next-generation sequencing and liquid biopsy techniques for accurate, personalized, and effective diagnosis, further augment the market.
The rapid and comprehensive analysis of patient genetic material with unprecedented accuracy and depth contributes to its surging adoption. Other advantages, such as the ability of liquid biopsies to monitor disease progression over time and the potential for early detection & treatment adjustment, propel market growth.
Favorable initiatives taken by the government for the manufacturing and exporting of diagnostic kits & reagents have also played a pivotal role in the growth of the market. For instance, India has lifted export restrictions on diagnostic kits and reagents, including equipment such as cancer tissue diagnostics kits.
Several cancer diagnostics manufacturing companies and healthcare facilities have seen a sizeable gap between the availability of skilled professionals and their needs. This shortage of experienced and skilled individuals, along with limited awareness, is hampering the market. Inadequate healthcare infrastructure and primary healthcare facilities, particularly in rural areas, are further limiting the accessibility of cancer tissue diagnostics.
The research study indicates that there are some underexplored fields of diagnostic product manufacturers in key countries. In accordance with the forecast, China and India are going to be a sizable area for cancer tissue diagnostic manufacturers to grow. But, the United States, United Kingdom, and Germany are taking advantage of their established markets, which means their growth rates are stable.
| Countries | Value CAGR (2024 to 2034) |
|---|---|
| United States | 3.1% |
| China | 6.8% |
| Germany | 2.5% |
| United Kingdom | 2.1% |
| India | 5.8% |
The United States dominates the global market with a 91.7% share in 2023 and is projected to continue experiencing stable growth throughout the forecast period. Increasing prevalence of cancer among the general population is fueling the adoption of cancer tissue diagnostics in the country, pushing market growth.
For instance, according to the statistics published by the Centers for Disease Control and Prevention in April 2023, in 2019, around 224,733 new cases of prostate cancer were reported in the United States. Increasing prevalence of cancer in the country is largely due to genetic complexity, rising drug use among the millennial population, and sedentary lifestyle of the general population.
China is set to lead the market at a CAGR of 6.8% through 2034. Research universities' increasing investment in cancer diagnosis programs and precision medicine research is propelling market growth in China.
The growing focus of regulatory bodies on initiating new programs for screening genetic mutations among individuals in China is contributing to the market's growth. For instance, according to a journal published by Precision Cancer Medicine in 2021, Fudan University Shanghai Cancer Center (FUSCC) in China launched a new program for screening BRCA mutations using next-generation sequencing (NGS).
In 2023, Germany held a significant global market share of 25% and is anticipated to maintain considerable growth over the forecast period. Increasing awareness of the surging prevalence of breast cancer among women in Germany is propelling growth of the tissue diagnostics product market.
Increasing prevalence of breast cancer has led to a surging adoption of cancer tissue diagnostics products, prompting manufacturers to broaden their distribution channels. For instance, in April 2023, Cerca Biotech collaborated with Sysmex Europe, a laboratory equipment supplier in Germany, to distribute their RT-qPCR molecular breast cancer assay in 13 European markets.
Check Free Sample Report & Save 40%!
Select your niche segments and personalize your insights for smart savings. Cut costs now!
The segmented cancer tissue diagnostic analysis is mentioned in the following subsection. Based on comprehensive studies, the molecular diagnostics test kits segment is leading the product type category. Similarly, the breast cancer segment is commanding the cancer type category.
| Product Type | Molecular Diagnostics Test Kits |
|---|---|
| Value CAGR (2024 to 2034) | 3.7% |
The molecular diagnostics test kit segment is set to lead the market, accounting for 42.7% market share in 2023, and is projected to grow at a substantial rate by 2034. Growth of molecular diagnostic test kits is propelled by increasing demand for personalized medicine, genomic research developments, and rapid diagnostic solutions. Moreover, their ability to conduct essential testing of infectious diseases with rapid and accurate results anticipates its growth.
| Cancer Type | Value CAGR (2024 to 2034) |
|---|---|
| Breast Cancer | 5.1% |
| Lung Cancer | 4.5% |
The breast cancer segment held a market share of 22.7% in 2023 and is projected to continue experiencing high growth throughout the forecast period. The rising prevalence of breast cancer among women due to aging, genetic mutations, and changing lifestyles has become a notable concern in recent years. Increasing prevalence of breast cancer is surging growth of the breast cancer segment through the increased use of cancer tissue diagnostics.
| End-user | Value CAGR (2024 to 2034) |
|---|---|
| Hospitals | 5.4% |
| Specialty Centers | 4.1% |
The hospital segment dominated the market and held a market share of 34.4% in 2023. Increasing awareness of different types of cancers has contributed to rising patient footfall in hospital facilities for routine check-ups. In addition, continuously improving healthcare infrastructure in developed and developing countries propels its expansion.
In the dynamic market landscape, companies emphasize launching new products to broaden their portfolio. Moreover, they are focusing on strategic collaborations and partnerships to address evolving market demands and extend their geographic footprint. Leading companies are directed toward product launches and developments to strengthen their market hold.
For instance
The market is set to reach USD 15,302.2 million in 2024.
Demand for cancer tissue diagnostics is slated to rise at a 4.5% CAGR by 2034.
The market is set to reach USD 23,516.2 million in 2034.
Abbott Laboratories, F. Hoffman-La Roche Ltd., and Thermo Fisher Scientific Inc. are the key players.
Breast cancer segment is estimated to hold a significant market share in 2024.
| Estimated Size, 2024 | USD 60.4 billion |
|---|---|
| Projected Size, 2034 | USD 136.7 billion |
| Value-based CAGR (2024 to 2034) | 8.5% |
| Expected Market Value (2023) | USD 9 Billion |
|---|---|
| Anticipated Forecast Value (2033) | USD 24.22 Billion |
| Projected Growth Rate (2023 to 2033) | 12% CAGR |
Explore Life Science & Biotechnology Insights
View Reports
Cancer Tissue Diagnostic Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
